GlassScriptPhysician profile
Warren B Chin
NPI 1740390681
$2,485.56
in general payments reported to CMS, 2019-2025
20 companies · $323 in 2025
The $323 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $496 · 2020: $258 · 2021: $216 · 2022: $360 · 2023: $553 · 2024: $278 · 2025: $323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,154.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $806.49 | 2021-2025 | Qulipta, Ubrelvy |
| Collegium Pharmaceutical, INC. | $511.55 | 2019-2025 | Belbuca |
| Teva Pharmaceuticals USA, INC. | $189.25 | 2019-2020 | |
| Vertex Pharmaceuticals Incorporated | $160.77 | 2025 | |
| Avanir Pharmaceuticals, INC. | $149.18 | 2021-2022 | |
| Biodelivery Sciences International, INC. | $121.44 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $102.51 | 2023-2024 | Nuedexta |
| Pfizer INC. | $76.36 | 2019-2025 | |
| Amgen INC. | $53.03 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $49.36 | 2021 | |
| Electronic Waveform Lab, INC. | $43.66 | 2019-2020 | |
| Assertio Therapeutics, INC. | $42.28 | 2019 | |
| Glaxosmithkline, LLC. | $41.90 | 2024-2025 | Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $36.33 | 2019-2020 | |
| Kaleo, INC. | $20.77 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $19.16 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.51 | 2024 | |
| Hikma Pharmaceuticals USA | $17.76 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.07 | 2022 | |
| Zyla Life Sciences, INC. | $11.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Warren Chin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.